Fenofibric Acid, immediate release tablet, 105 mg, a) 30 count bottle (NDC 53489-678-07), b) 90 ...
FDA Drug Recall #D-400-2014 — Class III — February 27, 2013
Recall Summary
| Recall Number | D-400-2014 |
| Classification | Class III — Low risk |
| Date Initiated | February 27, 2013 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Mutual Pharmaceutical Company, Inc. |
| Location | Philadelphia, PA |
| Product Type | Drugs |
Product Description
Fenofibric Acid, immediate release tablet, 105 mg, a) 30 count bottle (NDC 53489-678-07), b) 90 count bottle (NDC 53489-678-90), Rx only, Mutual Pharmaceutical Co., Inc., Philadelphia, PA 19124 USA
Reason for Recall
Labeling: Incorrect instructions; an error in section 5.11 of the patient insert that results in incorrect medical advice. Specifically, the labeling should read "If a severely depressed HDL-C level is detected, fibrate therapy should be withdrawn, and the HDL-C level monitored until it has returned to baseline, and fibrate therapy should not be re-initiated." The labeling for the recalled lots
Distribution Pattern
Nationwide and Puerto Rico.
Lot / Code Information
lot 6581105 & 6581106 exp. 07/15, and lot 6623001 & 6623002 exp. 01/16
Other Recalls from Mutual Pharmaceutical Company, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0572-2016 | Class II | Sulfamethoxazole and Trimethoprim Tablets, USP,... | Oct 9, 2015 |
| D-1424-2015 | Class III | Imipramine HCl Tablets, USP, 25 mg, 100 count b... | Jul 16, 2015 |
| D-1420-2015 | Class III | Felodipine Extended-Release Tablets, 2.5 mg, 10... | Jul 16, 2015 |
| D-1425-2015 | Class III | Imipramine HCl Tablets, USP, 50 mg, 100 count b... | Jul 16, 2015 |
| D-1421-2015 | Class III | Felodipine Extended-Release Tablets, 5 mg, 100... | Jul 16, 2015 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.